Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2017

22 March 2018 | Regulatory

Lund — 22 March 2018 — Camurus (CAMX) today announces that the Annual Report for 2017 now is available at the company’s website:

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92

TypeError: Cannot read properties of undefined (reading 'url')